5TY-27899-40643
4 vaccinations
1 coded response
13 check-ins
0 free-text entries
0 call cases
- Sex
- Female
- Age at first dose
- 31-35
- ZIP prefix
- 112 / NY
- Registered
- 2022-11-30
- Relationship
- Self
- Race
- White
- Ethnicity
- Not Hispanic or Latino
Timeline
-
2021-05-20
Dose 1 — Pfizer-BioNTech
-
2021-06-10
Dose 2 — Pfizer-BioNTech
-
2021-12-12
Dose 3 — Pfizer-BioNTech
-
2022-11-29
Dose 4 — Moderna
-
2022-11-30
Registered in v-safe
-
2022-11-30
Health check-in — days 1–6 daily, dose 4Feeling: Poor · Site: Pain · Fever · Chills, Headache, Muscle or body aches, Fatigue or tiredness · Be unable to work or attend school, Be unable to do your normal daily activitiesAdult check-in
-
2022-12-01
Health check-in — days 1–6 daily, dose 4Feeling: Fair · Site: Pain · Headache, Muscle or body aches, Fatigue or tiredness · Be unable to do your normal daily activitiesAdult check-in
- 2022-12-02
- 2022-12-03
- 2022-12-05
- 2022-12-08
- 2022-12-13
- 2022-12-20
- 2022-12-27
-
2023-01-05
Survey response — day 35, dose 4MedDRA: Nasopharyngitis — Feeling: Fair · Be unable to do your normal daily activitiesMedDRA releases: 2024-11
- 2023-01-10
- 2023-02-28
- 2023-05-30
Vaccinations
| Dose | Date | Manufacturer | Co-administered |
|---|---|---|---|
| 1 | 2021-05-20 | Pfizer-BioNTech | No |
| 2 | 2021-06-10 | Pfizer-BioNTech | No |
| 3 | 2021-12-12 | Pfizer-BioNTech | No |
| 4 | 2022-11-29 | Moderna | No |
Free text
None.
Each entry is dated by the survey it was written in (the CDC re-sent the releases with survey dates in 2025); click a date to see that survey response. The CDC cut some text off at about 250 characters: symptoms in every release, and the other two fields in releases 9-12. Those entries are marked "cut off by CDC".
MedDRA terms by release
| Field | Preferred term | 2021-09 | 2023-04 | 2024-11 |
|---|---|---|---|---|
| SD | Nasopharyngitis | · | · | ✓ |
✓ active code · ○ coded but marked inactive · blank = not in that release